Vitamin D Deficiency in Patients with Active Systemic Lupus Erythematosus

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2008 Jul 5

PMID 18600287

Citations 67

Authors

V Z C Borba

J G H Vieira

T Kasamatsu

S C Radominski

E I Sato

M Lazaretti-Castro

Affiliations

Soon will be listed here.

Abstract

Unlabelled: We investigated the effects of disease activity on bone metabolism in 36 patients with systemic lupus erythematosus (SLE). Changes in bone remodeling were not explained by corticosteroid use. A high prevalence of 25OHD deficiency in SLE patients indicates the need for vitamin D replacement, mainly during high disease activity periods.

Introduction: We investigated the effects of SLE disease activity on bone metabolism, their relation to inflammatory cytokines and vitamin D levels.

Methods: We performed a cross-sectional analysis of 36 SLE patients classified according to the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in high activity (group I: 12 patients, mean age 29.6 years) or in minimal activity (group II: 24 patients, mean age 30.0 years), and compared them to normal controls (group III: 26 women, 32.8 years). Serum calcium, phosphorus, parathyroid and sex hormones, bone remodeling markers, interleukin (IL)-6, soluble IL-6 receptor (sIL-6R), IL-1, tumor necrosis factor-alpha (TNF), 25-hydroxivitamin D (25OHD), and 1,25-dihydroxyvitamin D3 were measured, plus bone mineral density.

Results: All cytokines were significantly higher in SLE groups; IL-6 could differentiate SLE patients from controls. In group I, 25OHD levels were lower (P < 0.05), which was related to the SLEDAI (R = -0.65, P < 0.001). In multiple regression analysis, the 25OHD level was associated with SLEDAI, osteocalcin and bone-specific alkaline phosphatase. The SLEDAI score was positively correlated with all measured cytokines and especially TNF (R = 0.75, P < 0.001).

Conclusions: SLE patients demonstrated changes in bone remodeling strongly related to disease activity. A high prevalence of 25OHD deficiency was observed in SLE patients, indicating the need for vitamin D replacement.

Citing Articles

Leveraging machine learning to evaluate factors influencing vitamin D insufficiency in SLE patients: A case study from southern Bangladesh.

Saha M, Deb A, Sultan I, Paul S, Ahmed J, Saha G PLOS Glob Public Health. 2023; 3(10):e0002475.

PMID: 37906537 PMC: 10617712. DOI: 10.1371/journal.pgph.0002475.

Differential impact of environmental factors on systemic and localized autoimmunity.

Touil H, Mounts K, De Jager P Front Immunol. 2023; 14:1147447.

PMID: 37283765 PMC: 10239830. DOI: 10.3389/fimmu.2023.1147447.

Epidemiology of Vitamin D (EpiVida)-A Study of Vitamin D Status Among Healthy Adults in Brazil.

Borba V, Lazaretti-Castro M, Moreira S, Almeida M, Moreira Jr E J Endocr Soc. 2022; 7(1):bvac171.

PMID: 36518902 PMC: 9728789. DOI: 10.1210/jendso/bvac171.

Life factors acting on systemic lupus erythematosus.

Chen J, Liao S, Pang W, Guo F, Yang L, Liu H Front Immunol. 2022; 13:986239.

PMID: 36189303 PMC: 9521426. DOI: 10.3389/fimmu.2022.986239.

An Update on the Effects of Vitamin D on the Immune System and Autoimmune Diseases.

Sirbe C, Rednic S, Grama A, Pop T Int J Mol Sci. 2022; 23(17).

PMID: 36077185 PMC: 9456003. DOI: 10.3390/ijms23179784.

References

Lee C, Almagor O, Dunlop D, Manzi S, Spies S, Chadha A . Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology (Oxford). 2005; 45(1):53-60. DOI: 10.1093/rheumatology/kei079. View

Houssiau F, Lefebvre C, Depresseux G, Lambert M, Devogelaer J, Nagant de Deuxchaisnes C . Trabecular and cortical bone loss in systemic lupus erythematosus. Br J Rheumatol. 1996; 35(3):244-7. DOI: 10.1093/rheumatology/35.3.244. View

Bultink I, Lems W, Kostense P, Dijkmans B, Voskuyl A . Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005; 52(7):2044-50. DOI: 10.1002/art.21110. View

Bombardier C, Gladman D, Urowitz M, Caron D, Chang C . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992; 35(6):630-40. DOI: 10.1002/art.1780350606. View

Sels F, Dequeker J, Verwilghen J, Mbuyi-Muamba J . SLE and osteoporosis: dependence and/or independence on glucocorticoids. Lupus. 1996; 5(2):89-92. DOI: 10.1177/096120339600500202. View

Linker-Israeli M, Deans R, Wallace D, Prehn J, Klinenberg J . Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol. 1991; 147(1):117-23. View

Linker-Israeli M, Elstner E, Klinenberg J, Wallace D, Koeffler H . Vitamin D(3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. Clin Immunol. 2001; 99(1):82-93. DOI: 10.1006/clim.2000.4998. View

Tan E, Cohen A, Fries J, MASI A, McShane D, Rothfield N . The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982; 25(11):1271-7. DOI: 10.1002/art.1780251101. View

Luporini Saraiva G, Cendoroglo M, Ramos L, Araujo L, Vieira J, Kunii I . Influence of ultraviolet radiation on the production of 25 hydroxyvitamin D in the elderly population in the city of São Paulo (23 degrees 34'S), Brazil. Osteoporos Int. 2005; 16(12):1649-54. DOI: 10.1007/s00198-005-1895-3. View

10.

ORegan S, Chesney R, Hamstra A, Eisman J, OGorman A, DeLuca H . Reduced serum 1,25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr Scand. 1979; 68(1):109-11. DOI: 10.1111/j.1651-2227.1979.tb04969.x. View

11.

BOWERS Jr G, Rains T . Measurement of total calcium in biological fluids: flame atomic absorption spectrometry. Methods Enzymol. 1988; 158:302-19. DOI: 10.1016/0076-6879(88)58062-x. View

12.

Vaisberg M, Kaneno R, Franco M, Mendes N . Influence of cholecalciferol (vitamin D3) on the course of experimental systemic lupus erythematosus in F1 (NZBxW) mice. J Clin Lab Anal. 2000; 14(3):91-6. PMC: 6808021. DOI: 10.1002/(sici)1098-2825(2000)14:3<91::aid-jcla2>3.0.co;2-o. View

13.

Manolagas S . Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000; 21(2):115-37. DOI: 10.1210/edrv.21.2.0395. View

14.

Spronk P, ter Borg E, Limburg P, Kallenberg C . Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity?. Clin Exp Immunol. 1992; 90(1):106-10. PMC: 1554549. DOI: 10.1111/j.1365-2249.1992.tb05840.x. View

15.

Aringer M, Smolen J . Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus. 2004; 13(5):344-7. DOI: 10.1191/0961203303lu1024oa. View

16.

Chun H, Chung J, Kim H, Yun J, Jeon J, Ye Y . Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol. 2007; 27(5):461-6. DOI: 10.1007/s10875-007-9104-0. View

17.

Redlich K, Ziegler S, Kiener H, Spitzauer S, Stohlawetz P, Bernecker P . Bone mineral density and biochemical parameters of bone metabolism in female patients with systemic lupus erythematosus. Ann Rheum Dis. 2000; 59(4):308-10. PMC: 1753103. DOI: 10.1136/ard.59.4.308. View

18.

Hansen M, Halberg P, Kollerup G, Horslev-Petersen K, Hyldstrup L, Lorenzen I . Bone metabolism in patients with systemic lupus erythematosus. Effect of disease activity and glucocorticoid treatment. Scand J Rheumatol. 1998; 27(3):197-206. DOI: 10.1080/030097498440813. View

19.

Lee C, Almagor O, Dunlop D, Manzi S, Spies S, Ramsey-Goldman R . Self-reported fractures and associated factors in women with systemic lupus erythematosus. J Rheumatol. 2007; 34(10):2018-23. View

20.

Muller K, Kriegbaum N, Baslund B, Sorensen O, Thymann M, Bentzen K . Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol. 1995; 14(4):397-400. DOI: 10.1007/BF02207671. View